Company Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD).
Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial.
The company is also developing VY-FXN01 for treating friedreich’s ataxia; and GBA1 gene replacement program to treat parkinson’s disease.
In addition, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system.
Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 172 |
| CEO | Alfred Sandrock |
Contact Details
Address: 75 Hayden Avenue Lexington, Massachusetts 02421 United States | |
| Phone | 857 259 5340 |
| Website | voyagertherapeutics.com |
Stock Details
| Ticker Symbol | VYGR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001640266 |
| CUSIP Number | 92915B106 |
| ISIN Number | US92915B1061 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Trista Morrison | Chief Corporate Affairs Officer and Chief of Staff to the Chief Executive Officer |
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Toby Ferguson M.D., Ph.D. | Chief Medical Officer |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Robin Swartz | Chief Business Officer and Chief Operating Officer |
| Todd Carter Ph.D. | Chief Scientific Officer |
| Jacquelyn Fahey Sandell Esq., J.D. | Chief Legal Officer |
| Michelle Quinn Smith | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 24, 2025 | SCHEDULE 13G/A | Filing |
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2025 | 144 | Filing |
| Apr 2, 2025 | 144 | Filing |
| Mar 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2025 | 10-K | Annual Report |